1. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
- Author
-
Ulahannan SV and Brahmer JR
- Subjects
- Angiogenesis Inhibitors adverse effects, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Bevacizumab, Carcinoma, Non-Small-Cell Lung blood supply, Carcinoma, Non-Small-Cell Lung pathology, Humans, Lung Neoplasms blood supply, Lung Neoplasms pathology, Molecular Targeted Therapy, Protein Kinase Inhibitors administration & dosage, Risk Assessment, Treatment Outcome, Angiogenesis Inhibitors administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
- Published
- 2011
- Full Text
- View/download PDF